We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18

MedXY Editorial Team•Nov 15, 2025•Hematology-Oncology
acute myeloid leukemiaCPX-351gemtuzumab ozogamicinolder adults

Highlights

– In 439 patients ≥60 years without adverse‑risk cytogenetics enrolled to NCRI AML18, DAGO2 produced higher post‑course‑1 CR/CRi and MRD‑negative CR rates than CPX‑351.

– Three‑year event‑free survival (EFS) and overall survival (OS) favored DAGO2: 3‑yr EFS 34% vs 27% (HR 0.73, p=0.012) and 3‑yr OS 52% vs 35% (HR 0.62, p=0.001).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare DataAmong older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitoriSep 19, 2026Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged AdultsA phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan rSep 18, 2026Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALLA phase 1 trial of XmAb18968, a CD38-CD3 bispecific antibody, demonstrates safety and encouraging efficacy in heavily pretreated relapsed/refractory AML and T-ALL patients, highlighting a novel therapeutic avenue.Sep 18, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry
In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acut
Sep 17, 2026
Rethinking Surgical Quality Metrics: The Role of Operative-to-Nonoperative Management Ratio in Elderly Emergency General Surgery OutcomesThis study analyzes how the balance between operative and nonoperative management in emergency general surgery for older adults relates to their odds of discharge home, proposing ONR as a novel quality benchmark beyond traditional metrics.Sep 15, 2026
Unveiling the Cardiovascular Toll of Long-Term Wildfire Smoke PM2.5 Exposure in Older AmericansLong-term cumulative exposure to wildfire smoke PM2.5 significantly increases cardiovascular hospitalizations among U.S. older adults, with notable risks in ischemic heart disease and arrhythmias, highlighting the need for targeted public hSep 15, 2026